Latest News

New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years

MIAMI–(BUSINESS WIRE)–lt;a href="" target="_blank"gt;$MDCOlt;/agt; lt;a href="" target="_blank"gt;#cholesterollt;/agt;–The Medicines Company (NASDAQ: MDCO) today announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing with inclisiran sodium 300 mg resulted in consistent lowering of low density lipoprotein cholesterol (LDL-C) by more than 50 percent with overall follow-up of up to three years. Inclisiran was well tolerated, and no material safety issues were observed in the study. These results were presented tod

Source link

Related posts

New nitrides: from high pressure-high temperature synthesis to layered nanomaterials and energy applications


A Collaborative Project Between Industry and Academia to Enhance Engineering Education at Graduate and PhD Level in Ceramic Technology


Former Carers' Views on Assisted Dying in Dementia


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World